Eli Moses, MD
Ophthalmology · Dallas, TXNPI 1750515623
Payments from drug & device makers
Across 372 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$3K
- Glaukos Corporation$1K
- Biotissue Holdings Inc.$1K
- Bausch & Lomb Americas Inc.$671
- Mallinckrodt Hospital Products Inc.$669
- Dompe US, Inc.$667
- plus $4K from 21 others
What the payments were for
- Speaking & faculty fees$1,50013%
- Food & beverage$10,32386%
- Education$1001%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 12 | $3,384 |
| Glaukos Corporation | 10 | $1,275 |
| Biotissue Holdings Inc. | 33 | $1,063 |
| Bausch & Lomb Americas Inc. | 30 | $671 |
| Mallinckrodt Hospital Products Inc. | 38 | $669 |
| Dompe US, Inc. | 36 | $667 |
| Eyevance Pharmaceuticals LLC | 27 | $450 |
| Oyster Point Pharma, Inc. | 22 | $388 |
| Alcon | 10 | $381 |
| Kala Pharmaceuticals, Inc. | 23 | $375 |
| Harrow Eye, LLC | 7 | $336 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $307 |
| AbbVie(2 entities) | 12 | $293 |
| Sight Sciences, Inc. | 5 | $284 |
| Novartis | 19 | $263 |
| ANI Pharmaceuticals, Inc. | 13 | $218 |
| Sun Pharmaceutical Industries Inc. | 13 | $192 |
| Mallinckrodt Enterprises LLC | 9 | $128 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $124 |
| Rxsight Inc | 2 | $123 |
| Shire North American Group Inc | 8 | $114 |
| Tarsus Pharmaceuticals, Inc. | 6 | $107 |
| Amgen | 3 | $48 |
| Ocular Therapeutix, Inc. | 2 | $29 |
| Santen Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$533
- AmnioGraft$533
- Ahmed Glaucoma Valve$453
- Kahook Dual Blade$453
- iStent inject W$450
- iStent inject Trabecular Micro-Bypass Stent System$429
- iDose$338
- Streamline Surgical System$331
- IACCESS$309
- enVista MX60 IOL$278
- Oxervate$212
- KXL System$158
- Photrexa$158
- LUMIGAN$124
- OMNI$120
- OMNI(R) SURGICAL SYSTEM (US)$116
- SION SURGICAL INSTRUMENT$116
- AmnioGuard$116
- ReSTOR$102
- RXSIGHT CONTACT LENS$100
How this compares
$11,943 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $30,393 |
| Lotemax SmLoteprednol Etabonate | 77 | $27,508 |
| Prednisolone Acetate | 661 | $25,110 |
| XiidraLifitegrast | 21 | $24,787 |
| Fluorometholone | 112 | $10,600 |
| Loteprednol Etabonate | 54 | $9,459 |
| Cyclosporine | 29 | $9,281 |
| Difluprednate | 61 | $6,885 |
| Ofloxacin | 414 | $5,199 |
| Ketorolac Tromethamine | 349 | $4,835 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 26 | $4,406 |
| ValacyclovirValacyclovir Hcl | 82 | $3,511 |
| MoxifloxacinMoxifloxacin Hcl | 108 | $2,004 |
| ErythromycinErythromycin Base | 31 | $366 |
| Doxycycline Hyclate | 21 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $307 | $36,967131 claims |
| AbbVieRestasis | $293 | $30,39333 claims |
| Bausch & Lomb Americas Inc.Xiidra | $671 | $24,78721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Jeffrey WhitmanDallas$1.7M
- Oluwatosin SmithDallas$1.7M
- Davinder GroverDallas$1.3M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.